Risk factors for developing dyskinesia among Parkinson's disease patients with wearing-off: J-FIRST

[1]  Y. Shimo,et al.  Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST). , 2021, Parkinsonism & related disorders.

[2]  A. Guerra,et al.  Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia , 2021, Journal of experimental pharmacology.

[3]  R. Hauser,et al.  Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease , 2021, Expert review of neurotherapeutics.

[4]  A. Xie,et al.  Zonisamide for the Treatment of Parkinson Disease: A Current Update , 2020, Frontiers in Neuroscience.

[5]  A. Kaye,et al.  Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review , 2020, Neurology international.

[6]  Kelly A. Mills,et al.  Apathy and Anxiety in De Novo Parkinson's Disease Predict the Severity of Motor Complications , 2020, Movement disorders clinical practice.

[7]  Y. Sohn,et al.  Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson’s disease , 2020, PloS one.

[8]  Baihua Sun,et al.  Analysis of Motor Complication and Relative Factors in a Cohort of Chinese Patients with Parkinson's Disease , 2020, Parkinson's disease.

[9]  Y. Shimo,et al.  Motor/Nonmotor Symptoms and Progression in Patients with Parkinson's Disease: Prevalence and Risks in a Longitudinal Study , 2020, Parkinson's disease.

[10]  Y. Shimo,et al.  Real‐World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J‐FIRST , 2020, Movement disorders clinical practice.

[11]  D. Hernandez,et al.  Differences in the Presentation and Progression of Parkinson's Disease by Sex , 2020, medRxiv.

[12]  J. Kulisevsky,et al.  Non‐motor symptom burden is strongly correlated to motor complications in patients with Parkinson’s disease , 2020, European journal of neurology.

[13]  M. Okun,et al.  Diagnosis and Treatment of Parkinson Disease: A Review. , 2020, JAMA.

[14]  E. Moro,et al.  Sex differences in movement disorders , 2020, Nature Reviews Neurology.

[15]  E. Lane,et al.  Patterns and Determinants of Prescribing for Parkinson's Disease: A Systematic Literature Review , 2019, Parkinson's disease.

[16]  J. Klein,et al.  Predictors of motor complications in early Parkinson's disease: A prospective cohort study , 2019, Movement disorders : official journal of the Movement Disorder Society.

[17]  D. Centonze,et al.  Continuous subcutaneous apomorphine infusion in Parkinson’s disease: causes of discontinuation and subsequent treatment strategies , 2019, Neurological Sciences.

[18]  B. S. Ye,et al.  Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD , 2019, Neurology.

[19]  D. Maucort-Boulch,et al.  Age and time course of long-term motor and nonmotor complications in Parkinson disease , 2018, Neurology.

[20]  P. Calabresi,et al.  Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts , 2018, Annals of neurology.

[21]  P. Calabresi,et al.  Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort , 2018, npj Parkinson's Disease.

[22]  D. Aarsland,et al.  Risk factors for non-motor symptoms in Parkinson's disease , 2018, The Lancet Neurology.

[23]  L. Saba,et al.  Correlation among olfactory function, motors’ symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson’s disease , 2018, Journal of Neurology.

[24]  Y. Song,et al.  The non-motor symptoms of Parkinson's disease of different motor types in early stage. , 2017, European review for medical and pharmacological sciences.

[25]  R. Marconi,et al.  Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study , 2017, Movement disorders : official journal of the Movement Disorder Society.

[26]  Y. Shimo,et al.  Clinical manifestations of nonmotor symptoms in 1021 Japanese Parkinson's disease patients from 35 medical centers. , 2017, Parkinsonism & related disorders.

[27]  S. Fox,et al.  Motor Complications of Dopaminergic Medications in Parkinson's Disease , 2017, Seminars in Neurology.

[28]  P. Martínez-Martín,et al.  Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease , 2017, Journal of the Neurological Sciences.

[29]  Y. Mizuno,et al.  Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs , 2017, Journal of Neural Transmission.

[30]  Paolo Barone,et al.  The relevance of gender in Parkinson’s disease: a review , 2017, Journal of Neurology.

[31]  M. Rosas,et al.  Parkinson's Disease and development of levodopa induced motor complications: Influence of baseline features and first medical approach. , 2016 .

[32]  E. Tan,et al.  The impact of non‐motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study , 2016, European journal of neurology.

[33]  R. Camicioli,et al.  Parkinson Disease: The Relationship Between Non-motor Symptoms and Motor Phenotype , 2015, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[34]  I. Kanazawa,et al.  Zonisamide improves wearing‐off in Parkinson's disease: A randomized, double‐blind study , 2015, Movement disorders : official journal of the Movement Disorder Society.

[35]  M. Guido,et al.  Action tremor in Parkinson's disease: frequency and relationship to motor and non‐motor signs , 2015, European journal of neurology.

[36]  M. Cenci,et al.  Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications , 2014, Front. Neurol..

[37]  Marianna Amboni,et al.  The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa , 2014, Brain : a journal of neurology.

[38]  S. Ikeda,et al.  Prescribing Pattern of Anti-Parkinson Drugs in Japan: A Trend Analysis from 2005 to 2010 , 2014, PloS one.

[39]  Y. Shimo,et al.  Motor and non-motor symptoms of 1453 patients with Parkinson's disease: prevalence and risks. , 2013, Parkinsonism & related disorders.

[40]  Murat Emre,et al.  Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[41]  M. Stacy,et al.  Patient perspectives on Parkinson’s disease therapy in Japan and the United States: results of two patient surveys , 2012, Patient related outcome measures.

[42]  A. Pisani,et al.  The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life , 2012, Journal of Neurology.

[43]  P. Jenner,et al.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation , 2011, Journal of Neural Transmission.

[44]  Thomas Foltynie,et al.  The natural history of treated Parkinson's disease in an incident, community based cohort , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[45]  M. Murata.  Zonisamide: a new drug for Parkinson's disease. , 2010, Drugs of today.

[46]  K. Sethi.  The Impact of Levodopa on Quality of Life in Patients With Parkinson Disease , 2010, The neurologist.

[47]  I. Kanazawa,et al.  Zonisamide improves motor function in Parkinson disease , 2007, Neurology.

[48]  H. Apaydin,et al.  A hospital-based study: Risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy , 2006, Clinical Neurology and Neurosurgery.

[49]  L. Shulman,et al.  Gender disparities in Parkinson’s disease , 2006, Expert review of neurotherapeutics.

[50]  P. Vieregge,et al.  Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study , 2005, European journal of neurology.

[51]  Laurent Gerbaud,et al.  Impact of the motor complications of Parkinson's disease on the quality of life , 2005, Movement disorders : official journal of the Movement Disorder Society.

[52]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[53]  Y. Shimo,et al.  Motor and Non-Motor Symptoms of 1453 Patients with Parkinson ’ s Disease : Any Relationship with the Cumulative Doses of Anti-Parkinsonian Medications ? , 2014 .

[54]  A. Schrag,et al.  Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. , 2012, Journal of Parkinson's disease.

[55]  B. Robottom.  The natural history of treated Parkinson's disease in an incident, community based cohort , 2012 .